<DOC>
	<DOC>NCT01386099</DOC>
	<brief_summary>The purpose of this study is to investigate the pharmacokinetics and pharmacodynamics of PSN821 in patients with type 2 diabetes. Subjects will be assessed for beta-cell function using a hyperglycaemic clamp before the start of treatment and at the end of a 12 week treatment period as the primary endpoint. HbA1c, fasting plasma glucose and body weight are secondary endpoints.</brief_summary>
	<brief_title>A PK-PD Study of PSN821 in Type 2 Diabetes Patients (T2DM)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Patients with Type 2 diabetes according to the American Diabetes Association criteria, diagnosed at least 12 months prior to screening. Male or female, between 18 and 75 years of age, inclusive. Body Mass Index of 25 45 kg/m2, inclusive. Diabetes managed on a stable regimen of diet, exercise and metformin monotherapy (without dosage adjustments within 4 weeks prior to screening). Haemoglobin A1c (HbA1c) of 7.5 10% at screening. Fasting plasma glucose (FPG) of between 7 13.3 mmol/L at screening and Day 1. Males who are, and whose partners are able to comply with contraceptive advice. Females of non childbearing potential. Willing to sign the written Informed Consent Form (ICF) to participate in the study and to abide by the study restrictions. Patients with Type 1 diabetes or maturity onset diabetes of the young or secondary forms of diabetes, such as due to pancreatitis. Marked diabetic complications. Illness or medication that impacts on the scientific integrity of the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>